EQT

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Founded in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies with strong growth potential in various sectors, including healthcare, technology, and industrials. EQT employs a responsible ownership approach and aims to create sustainable value through active management and strategic guidance. The firm's investment strategies include private capital, real assets, credit, and public value, targeting companies with consistent cash flows and meaningful intrinsic value. EQT is also known for its expertise in the life sciences sector, having transitioned its healthcare investment arm into EQT Life Sciences, which focuses on innovative healthcare companies. The firm typically invests between €50 million and €600 million, with a preference for controlling or co-controlling stakes in its portfolio companies, which it holds for an average of four to eight years.

Sofia Ahuja

Partner

CHRISTIAN SHIN HØEGH ANDERSEN

Managing Director, Private Equity and Investment Advisory Professional

James Arrol

Managing Director, Fund Management

Teruyuki Asaoka

Managing Director

Andreas Aschenbrenner

Partner

Fouad Azzam

Partner

Fredrik Backman

Managing Director, Client Relations

Peter Balslev

Managing Director

Johann-Christoph Balzer

Partner, EQT Value-Add Infrastructure

Michael Bauer

Partner, Head of Switzerland and Co-Head of EQT's Global Healthcare Sector Team

Eirik Benzon

Managing Director, BPEA EQT Team

William Bergström

Director

Lennart Blecher

Deputy Managing Partner

Clemens Van Blitterswijk

Founder of LSP Health Economics Fund

Mark Braganza

Partner, Investment Advisory

Marcus Brennecke

Institutional Partner, Marcus is a member of the Equity Partners Investment Committee and the Portfolio Performance Review Committee

Marc Brown

Partner and Head of EQT Growth

Nicolas Brugère

Partner and Head of France

Anna Brundtland

Managing Director

Philipp Bräuer

Associate

Drew Burdon

Partner

Caspar Callerstrom

Deputy CEO

Brian Chang

Partner

Kenneth Cheong

Partner

Henry Connon

Associate, Private Equity and Investment Advisory Professional

Crosby Cook

Partner, Infrastructure and Investment Advisory Professional

Guy Cui

Partner

Nicholas Curwen

Managing Director

Alex Darden

Partner, President and Head of EQT Infrastructure Advisory Team Americas

Johan Dettel

Partner

Mads Ditlevsen

Partner and Head of EQT Partners Denmark

Asís Echániz

Partner and Head of Spain

Andreas Eichelberger

Director

Frederik Elwing

Managing Director

Leeann Emmi

Vice President

Victor Englesson

Partner, Head of Private Equity Nordic and Co-Head of Global Technology Sector

Ali Farahani

Partner

Frank Feng

Managing Director

Michael Focking

Senior Partner

Mark Fogle

Partner and Head of EQT Exeter APAC

David Forde

Partner

Per Franzén

Head of Private Capital and Deputy Managing Partner

Juho Frilander

Managing Director

Joseph Fuda

Partner, Client Relations and Capital Raising

Florian Funk

Partner, Private Equity

Maria Gaffron

Associate, Infrastructure

Guillermo Garcia-Barrero

Managing Director

Carlos Garcia-Fuster

Partner, Private Equity

Henrik Giver

Managing Director

Simon Gold

Managing Director, Client Relations and Capital Raising

Wolfgang Gorny

Partner, Private Equity

Alexander Greenbaum

Partner, Active Core Infrastructure Advisory Team and Investment Advisory Professional

Fabian Grone

Partner, Infrastructure

Albert Gustafsson

COO of Private Capital Europe and North America

Floris van Halder

Managing Director

Sean Ham

Partner and Head of Asia Pacific

Kevin Hammon

Associate

Takanobu Hara

Partner

Jerry He

Partner and Head of China, Mid Market Asia Advisory Team

Frank Heckes

Partner, Private Equity

Erika Henriksson

Partner, Private Equity

Jak Hestnes

Managing Director and Board Member

Gerran Ho

Managing Director, Mid Market Asia

Christian Horn

Managing Director

Andreas Huber

Partner

Sara Huda

Managing Director and Head of Investment Services

Johan Daniel Hylander

Managing Director

Bert Janssens

Head of Private Equity Europe and Global Co-Head of Services, Private Capital

Patrick Jaslowitzer

Managing Director

Neha Jatar

Managing Director

Bjorn Jensen

Partner

Yan Jiao

Partner

Hakan Johansson

Senior Partner

Herman Johre

Associate

Maarten de Jong

Partner, EQT Private Equity

Nathalie Kaeser

Vice President, Private Equity

Kosmo Kalliarekos

Partner

Viviana Kane

Managing Director

Masahiko Kato

Managing Director and Head of Infrastructure Japan

Matthew Kestenbaum

Managing Director

Nils Ketter

Partner

Paul Kim

Managing Director

Jörg Kinberger

Partner, Private Equity

Cillian King

Managing Director

Martijn Kleijwegt

Managing Partner

Thomas Klews

Director

John de Koning

General Partner

Kees Koolen

Partner

Vesa Koskinen

Partner, Private Equity and Head of Finland

Gleb Kozyritskiy

Managing Director

Arvindh Kumar

Partner and Co-Head of Technology Sector Team

Elias Nissilä Källström

Managing Director

Ulrich Kollensperger

Partner

Tobias Küng

Managing Director, Infrastructure

Priscilla Lam

Managing Director, Portfolio Monitoring

Lance Lan

Managing Director, Exit Management

Adam Larsson

Managing Director

Robert Latz

Managing Director

Kenneth Lau

Associate

Edward Lavish

Managing Director, Portfolio Risk and Transactions

Juliette Lee

Associate

Eu Han Lee

Partner, Debt Capital Markets

Alex Lee

Partner

Hong Yong Leong

Partner

Janice Leow

Partner

William Liang

Director of European Firm

Benjamin Lim

Director

William Lindström

Managing Director

Gebhard Littich

Managing Director

Madeleine Magnerius

Director

Paola Maleh

Partner and Head of EMEA

Francesco Malvezzi

Managing Director, Infrastructure

Tadashi Maruoka

Partner

Axel Masucci

Managing Director

Arnav Mitra

Director

Martin Mix

Managing Director

Mikael Moll

Managing Director, Public Value

Jens Moritz

Partner

Maximilian Moser

Associate

Tomasz Muszynski

Director, Private Equity

Petri Myllyneva

Partner

Pascal Noel

Managing Director

Tetsuro Onitsuka

Partner and Head of Private Equity Japan

Alex Paganini

Associate, Infrastructure

Isabel de Paoli

Partner, Healthcare

Sydney Pardey

Managing Director

Tyler Parker

Managing Director

Daniel Perez

Partner

Christopher J. Popp

Managing Director

Anne Portwich

Partner

Shane Predeek

Partner

Federico Quitadamo

Partner and Head of Italy

Vai Rajan

Head of EMEA Private Wealth Capital Raising and Director - Client Relations and Capital Raising

Thomas Rajzbaum

Managing Director and Partner, EQT Infrastructure

Hermann Rauch

Managing Director

Vera Rebanova

Partner, Client Relations and Capital Raising

Johannes Reichel

Partner

Carl Renström

Partner

Matthias Riefer

Managing Director, Private Equity

Niklas Ringby

Partner and Co-Head of Public Value Advisory Team

Patrick Rodden

Managing Director and Head of Infrastructure for Australia and New Zealand

Maxwell Roitstein

Associate

Joachim Rothe

General Partner

Isidoor Rutten

Partner

Rob Ryan

Managing Director, Market Risk

Rosa Sammon, Darlene De La

Partner and Co-Head, Client Relations and Capital Raising

Carlos Santana

Partner

Anthony Santospirito

Partner

Mika Saukkonen

Managing Director, Infrastructure

Matthew Scattarella

Partner

Philip Scheltens

Managing Partner, Dementia Fund

Paul Schrotti

Partner

Nirav Shah

Partner, EQT Value-Add Infrastructure

Hemant Sharma

Managing Director

Gordon Shaw

Partner

Christian Sinding

CEO and Managing Partner

Piyush Singhvi

Managing Director, Infrastructure

Carl Sjölund

Partner, Infrastructure

Jared Small

Managing Director

Georg Stadler

Partner, Infrastructure

Dominik Stein

Partner and Head of EQT Growth Advisory Team

Joshua Stone

Managing Director, FO Head of Strategic Initiatives

Alexander Strassburger

Managing Director

Marc-Alexander Straubinger

Managing Director

Jan Stypulkowski

Managing Director

Sang Jun Suh

Partner

Anna Sundell

Partner, Infrastructure

Miriam Tawil

Partner and Investment Advisory Professional

Michiel Thiessen

Managing Director

Elly Thio

Managing Director

Erwin A. Thompson

Partner, Infrastructure

Matteo Thun

Partner

Andrew Tirbeni

Managing Director, EQT Client Relations and Capital Raising

Wei Jian Tor

Managing Director

Juan Vargas

Partner

Felice Verduyn

Investment Manager

Jan Vesely

Partner

Marcus Wallinder

Partner and Deputy Head of Client Relations and Capital Raising

Forrest Wang

Managing Director, Private Equity

Ethan Waxman

Partner

Mark Wegter

Managing Partner

Arno de Wilde

Investor

Rickard Wilson

Managing Director

Matthias Wittkowski

Partner

Ken Wong

Partner and Head of Asia Pacific, Infrastructure

Philipp R. Wörner

Director, Private Equity

Dayea Yeon

Managing Director and Head of Private Capital Korea

Shuting You

Managing Director

James Yu

Partner and Senior Bank Relationship Manager

Julia Zhu

Managing Director

Fredrik Åtting

Partner

John Österlund

Managing Director, Infrastructure

Stephan Leithner Ph.D

Partner

René Kuijten Ph.D

Managing Partner

Past deals in Switzerland

Arvelle Therapeutics

Series A in 2020
Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

FoRx Therapeutics

Seed Round in 2020
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. It specializes in developing innovative therapeutics for cancer treatment by targeting key molecular pathways involved in DNA replication stress. The company aims to create first-in-class compounds that represent a novel approach in the fight against cancer, focusing on drugging specific molecular targets associated with this replication stress. Through its research and development efforts, FoRx Therapeutics seeks to contribute to the advancement of targeted anticancer drugs within the healthcare industry.

SHL Medical

Private Equity Round in 2020
SHL Group, based in Zug, Switzerland, specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto injectors, pen injectors, and inhaler systems. Founded in 1989, the company provides comprehensive services, such as final assembly, labeling, and packaging, for pharmaceutical and biotech firms globally. SHL Group prioritizes compliance with strict regulations and upholds high-quality standards in its operations. The company emphasizes the importance of talent development and collaboration among its employees to enhance productivity and customer satisfaction. By focusing on these core principles, SHL Group aims to deliver superior business outcomes while maintaining professionalism in all aspects of its work.

Galderma

Acquisition in 2019
Galderma S.A. is a global company specializing in the manufacture and distribution of medical, consumer skin health, and dermatology products. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma offers a wide range of solutions including prescription medicines, medical aesthetics, and skincare products. Its extensive product portfolio addresses various dermatological conditions such as acne, rosacea, psoriasis, and skin cancer, with well-known brands like Epiduo®, Differin®, and Restylane®. The company operates through a network of 33 wholly-owned affiliates and distributors in approximately 80 countries, employing around 6,600 people. Galderma emphasizes innovation in meeting the dermatological needs of individuals and healthcare professionals, with research and development, and manufacturing sites located across multiple regions including Europe, Asia-Pacific, and the Americas.

Pharvaris

Series B in 2019
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Arvelle Therapeutics

Series A in 2019
Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Inspired

Private Equity Round in 2018
Inspired is a co-educational, non-denominational independent school group based in London, with additional locations in Johannesburg, South Africa. The organization operates a network of private schools across Europe, Australia, and Africa, including sites in Berkshire, Switzerland, Sydney, and several cities in South Africa such as Cape Town and Pretoria. Catering to students aged 1 to 18, Inspired aims to foster an environment that encourages academic achievement and personal growth. The school group emphasizes a progressive approach to education, reevaluating traditional teaching methods and curriculums to provide a more dynamic and relevant learning experience that reflects contemporary attitudes and prepares students for future challenges.

Xeltis

Series C in 2017
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Open Systems

Acquisition in 2017
Open Systems AG is a provider of managed security services, specializing in network security, application delivery, identity management, and global connectivity. The company offers a comprehensive range of services, including distributed and enterprise firewalls, WAN encryption, network security monitoring, and web application firewalls, among others. Open Systems also focuses on identity management solutions, such as federated identity management and single sign-on services. Its integrated service management capabilities encompass cloud solutions, WAN routing, and unified communications, catering to various sectors including government, finance, healthcare, and retail. Founded in 1990 and headquartered in Zurich, Switzerland, Open Systems operates additional offices in Sydney and New York, delivering 24/7 expertise to help enterprises securely scale in the cloud while effectively managing cyber threats.

CHEP

Acquisition in 2016
CHEP specializes in enhancing supply chain efficiency through innovative solutions that help customers reduce costs, increase sales, and improve sustainability. The company is particularly recognized for its asset management and repair services in the aerospace sector, focusing on Unit Load Devices (ULDs), galley carts, and ground support equipment. Headquartered in Zurich, Switzerland, CHEP Aerospace Solutions operates the world's largest independent fleet of ULDs and maintains a vast global network for the repair and maintenance of containers, pallets, and in-flight food service equipment. By offering tailored outsourcing solutions, CHEP supports over 80 airlines worldwide, allowing them to concentrate on their core operations while benefiting from significant operational efficiencies. Additionally, CHEP's services in China cater to fast-moving consumer goods and automotive sectors, providing sustainable alternatives to single-use products and proprietary platforms.

Unilode Aviation Solutions

Private Equity Round in 2016
Unilode Aviation Solutions, formerly known as CHEP Aerospace Solutions, is a prominent provider of unit load device (ULD) pooling, management, maintenance, and repair services tailored for the aviation sector. The company operates the world's largest independent fleet of approximately 100,000 ULDs and maintains an extensive global network dedicated to the maintenance and repair of ULDs and galley carts. By offering lightweight pooling options that include aluminum and lightweight containers, as well as standard and heavy-duty pallets, Unilode enables airlines and cargo carriers to reduce costs through outsourced ULD services. This approach allows clients to efficiently manage their ULD and galley cart fleets, enhancing operational effectiveness in the transportation of cargo and baggage on both passenger and cargo aircraft.

Nouscom

Series A in 2016
Nouscom is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Headquartered in Basel, Switzerland, with operations in Rome, Italy, the company specializes in engineered viral vector vaccines. Their platform is designed to express long strings of tumor neoantigens, facilitating the induction of strong antitumor T-cell responses to enhance cancer-specific cellular immunity. The leadership team, including experienced entrepreneurs like Prof. Riccardo Cortese, brings a wealth of expertise from previous successful ventures in the field of oncolytic and genetic vaccines.

Kuoni Group

Acquisition in 2016
Kuoni Group is a global leisure and destination management travel organization based in Zurich, Switzerland, with operations across Europe, Asia, Africa, Australia, and North America. Founded in 1906, it serves consumers through both online and offline channels. The company's core activities include Global Travel Distribution, which provides travel companies with access to hotel accommodations and destination services, and Global Travel Services, which coordinates a range of destination-related offerings, including tours and event management. Kuoni Group is a leader in the group travel market, handling around 50,000 leisure tours annually. Additionally, it operates VFS Global, a premier visa services provider for 48 governments, with a significant presence in the Asia/Pacific region. In 2015, Kuoni Group reported a turnover of CHF 3.35 billion and employed approximately 8,000 people, with a strong focus on sustainable growth in emerging markets.

Kuoni Reisen Holding

Acquisition in 2016
Kuoni Reisen Holding AG is a Switzerland-based company that serves the travel industry and governments through three main business areas. Its Global Travel Distribution (GTD) division focuses on hotel accommodations and destination services for travel companies and agents. The Global Travel Services (GTS) segment offers comprehensive destination management services, including accommodation, transportation, tours, activities, and event management. Additionally, the company provides Visa Facilitation Services (VFS) through various application centers, assisting with visa outsourcing in multiple countries. Kuoni also specializes in event solutions, catering to virtual, hybrid, and live events, offering services such as entertainment, technology, transportation, and logistics, while ensuring an engaging experience for attendees.

Pharvaris

Series A in 2016
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis

Series B in 2015
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Sequana Medical

Series C in 2015
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Kuros Biosciences

Post in 2015
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.

Xeltis

Series B in 2014
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Evidensia Djursjukvard

Acquisition in 2014
Evidensia Djursjukvård AB owns and operates veterinary hospitals and clinics in Sweden, Norway, Denmark, Finland, Holland, Germany, and Switzerland.

Sportradar

Private Equity Round in 2014
Sportradar AG is a prominent provider of sports-related live data and digital content services, catering to media companies, bookmakers, sports federations, and regulatory authorities globally. Established in 2001 and headquartered in Sankt Gallen, Switzerland, Sportradar focuses on the collection, processing, and commercialization of sports data. The company monitors the global betting market for unusual patterns and collaborates with sports federations and law enforcement to combat betting-related manipulations, including match-fixing. Sportradar offers a comprehensive range of products and services, including data collection, managed trading, live streaming, and various solutions for bookmakers, such as odds compilation and live data visualization. The company maintains a strong presence worldwide, with offices in major cities across Europe, Asia, and North America, and partners with leading international sports organizations to ensure the integrity and security of sports data.

Swiss Smile

Private Equity Round in 2013
Swiss Smile Holding AG operates a network of dental competence centers, providing a comprehensive range of dental services including aesthetic dentistry, bleaching, implantology, orthodontics, oral surgery, endodontics, pediatric dentistry, periodontology, and professional teeth cleaning. Established in 2002, the company caters to both local and international patients, with centers located in various Swiss cities such as Zurich, Baden, St. Moritz, Suhr, and Winterthur, as well as international locations including Bengaluru, Moscow, and London. Swiss Smile also offers dental hygiene products such as whitening toothpastes, toothbrushes, and interdental brushes. Additionally, the company emphasizes preventive care and education, offering dentistry classes in schools to promote oral health awareness.

Sportradar

Private Equity Round in 2012
Sportradar AG is a prominent provider of sports-related live data and digital content services, catering to media companies, bookmakers, sports federations, and regulatory authorities globally. Established in 2001 and headquartered in Sankt Gallen, Switzerland, Sportradar focuses on the collection, processing, and commercialization of sports data. The company monitors the global betting market for unusual patterns and collaborates with sports federations and law enforcement to combat betting-related manipulations, including match-fixing. Sportradar offers a comprehensive range of products and services, including data collection, managed trading, live streaming, and various solutions for bookmakers, such as odds compilation and live data visualization. The company maintains a strong presence worldwide, with offices in major cities across Europe, Asia, and North America, and partners with leading international sports organizations to ensure the integrity and security of sports data.

Atos Medical

Acquisition in 2011
Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.

SFC Koenig

Private Equity Round in 2008
SFC Koenig specializes in high-quality sealing and flow control technology, offering a diverse range of products and solutions tailored to meet precise customer needs. The company manufactures standard and customized solutions that enhance system reliability and efficiency while adhering to stringent safety and environmental standards. Its product lineup includes fastening and sealing technology, such as force-fitting fasteners, rivet systems, screw threads, adhesive products, and hydraulics expanders, which are utilized across various industries, including automotive, aerospace, electronics, medical engineering, and construction. By focusing on reducing waste and lowering lifecycle costs, SFC Koenig aims to deliver innovative solutions that not only optimize performance but also minimize damage to components.

Verisure

Acquisition in 2008
Verisure Sverige is a prominent provider of monitored security solutions tailored for residential and small business customers. Based in Malmö, Sweden, the company serves approximately 2 million clients across 14 countries in Europe and Latin America. Established in 1988, Verisure operates primarily under the brand name Verisure, while it is known as Securitas Direct in Spain and Portugal. The company is recognized for its commitment to delivering peace of mind and protection, with a new security system being installed globally every 30 seconds. As a subsidiary of Verisure Midholding AB, Verisure Sverige continues to expand its reach and enhance its service offerings in the security sector.

Vivendy Therapeutics

Series A in 2007
Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

PharmaZell

Debt Financing in 2007
PharmaZell GmbH develops and produces generic active pharmaceutical ingredients (API), controlled substances, and amino acids. The company also offers custom synthesis and finished dosage form development projects. It serves the pharmaceutical industry worldwide. The company was founded in 1947 and is based in Raubling, Germany with production plants in Liestal, Switzerland; Gropello Cairoli, Italy; and Chennai and Vizag, India. It also has a sales branch in Cleveland, Ohio. PharmaZell GmbH is a prior subsidiary of Zellbios S.A.

Okairos

Series A in 2007
Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

CBR

Acquisition in 2007
CBR Fashion Holding AG is a German company specializing in the wholesale and retail of women's apparel. Founded in 1980 and based in Celle, the company offers a diverse range of clothing items, including pants, denim, shirts, knitwear, and dresses, primarily under the Street One and Cecil brand names. Targeting women aged 25 to 50, CBR produces twelve collections annually for each label, ensuring rapid turnover and responsiveness to market trends. In addition to its wholesale activities, CBR operates retail stores, outlet locations, and an e-commerce platform. As of March 2015, the company managed 64 retail stores and 7 outlet stores in Germany, along with outlets in Switzerland and Italy. CBR Fashion Holding AG previously operated as CBR Fashion Holding GmbH until its name change in June 2015.

4-Antibody

Series A in 2007
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

4-Antibody

Seed Round in 2004
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.